PHARMACY

McKesson Specialty names medical director

BY Michael Johnsen

THE WOODLANDS, Texas — McKesson Specialty Health and the U.S. Oncology Network on Friday announced that Marcus Neubauer accepted the position of medical director of oncology services for McKesson Specialty Health, effective March 1. 

“Dr. Neubauer is a respected and impressive physician who is committed to advancing the quality and science of cancer care,” stated Roy Beveridge, chief medical officer for McKesson Specialty Health and the U.S. Oncology Network. “With more than two decades of medical experience and his intimate knowledge of pathways, diagnostics and community-based patient care, he is the perfect fit for this position.”

In his new role, Neubauer will serve as the primary medical liaison between physicians in the U.S. Oncology Network and physicians and executives within the National Comprehensive Cancer Network. This includes ensuring that the recently announced Value Pathways powered by NCCN are 100% concordant with NCCN Clinical Practice Guidelines in Oncology and that they are well integrated in a clinical quality and regimen support system — an important step in ensuring patients receive the highest quality treatment while offering options to address costs of cancer care, McKesson Specialty noted. 

Neubauer will serve as the physician lead for the suite of payer-facing solutions delivered to oncology providers, and will support the development and marketing of quality solutions and programs to providers, payers and employers.

Neubauer has been heavily involved in the U.S. Oncology Network for more than 15 years. He serves as chair of the U.S. Oncology Network Pathways Task Force, sits on the editorial board of the Journal of Oncology Practice and most recently served as an oncologist with Kansas City Cancer Center. He has been published more than 20 times and is a member of the American Society of Clinical Oncology. Neubauer is board certified in internal medicine and medical oncology.

keyboard_arrow_downCOMMENTS

Leave a Reply

B.Franklin says:
Aug-30-2013 05:01 am

Well that's really great we are hoping to get advanced and beneficial medical care service through different strategies after Marcus Neubauer enter into the position. We are really estimating certain high level changes in medical care system in McKesson Specialty Health. Definitely these kinds of changes should be essential in every health care sector. urgent care Cincinnati

TRENDING STORIES

PHARMACY

FDA approves Gleevec for most common pediatric cancer

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration has approved a Novartis drug for treating leukemia in children.

The FDA said Friday that it approved Gleevec (imatinib) for treating children newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia, also known as Ph+ ALL.

ALL is the most common type of cancer in children, the FDA said, affecting about 2,900 children per year. In children with Ph+ ALL, a genetic abnormality causes proteins called tyrosine kinases to stimulate the bone marrow to make too many immature white blood cells, leaving less room for healthy white blood cells to fight infection.

"We are pleased that the number of cancer medications for children are on the rise," FDA office of Hematology and Oncology Products director Richard Pazdur said. "Today’s approval is the result of continuous interactions among the FDA, the Children’s Oncology Group and the National Cancer Institute to provide new and better treatments to American children with cancer."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Dr. Reddy’s launches allergy drug

BY Alaric DeArment

HYDERABAD, India — Dr. Reddy’s Labs has launched a drug used for treating allergies, the generic drug maker said Friday.

The Indian drug maker announced the launch of desloratadine orally disintegrating tablets in the 2.5-mg and 5-mg strengths. The drug is a generic version of Merck’s Clarinex Reditabs and is available in unit-dose packages of 30.

The branded version of the drug had sales of about $5.3 million during the 12-month period that ended in November 2012, according to IMS Health.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES